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influenza (group C), and 8 healthy people who developed influenza
(group D.)
Methods: Case ascertainment through microbiology and electronic
medical records.
Results: Types of transplant: liver 3, heart 7, kidney 3, lung 8,
HSCT 8, kidney + pancreas 3, liver + kidney 1, liver + pancreas 1.
20 had influenza A, and 10 had influenza B (1 transplant recipi-
ent has both simultaneously.) Influenza occurred 1757 days (mean
[range 0-3850]) after transplant in group A, compared to 801 days
(range 20-3082) in group B. Influenza occurred 116 days (mean
[range 83-151] after vaccination in group A. There were no sta-
tistically significant differences in the incidence of fever, cough,
rhinorrhea, sore throat, malaise, shortness of breath, exposure to
contacts with similar symptoms, or presence of infiltrates on CXR
among groups A, B and D. Groups A and B were treated with os-
eltamivir significantly more frequently than Group D, [p=0.002].
Patients in group A were hospitalized more frequently than group
D [p=0.0002]. There were no statistically significant differences
in the incidence of pneumonia, ICU admission, mechanical ventila-
tion, or death among groups A, B and D. There were no statistically
significant differences between groups A, B and C in the incidence
of IgG < 600 mg/dL, immune function assay < 200 ng/mL, rejec-
tion (in SOT recipients) or GVHD (in HSCT recipients) in the preced-
ing 30 days. Patients in group A were significantly more likely to
have concomitant infections than group D [p=0.049], but not group
B.
Conclusions: Influenza vaccination did not alter clinical presenta-
tion of influenza in transplant recipients, or impact the incidence
of complications. Transplant recipients who developed influenza
despite influenza vaccination were not more immunosuppressed
than those who were vaccinated and did not develop influenza,
and were more likely to have concomitant infections than healthy
people.
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Background: Oral Candida carriage and/or infection have been re-
ported to be associated with a greater risk for esophagitis and
pneumonitis in renal and liver transplant recipients; however a sys-
tematic analysis of the oral Candida titers and species has not been
previously conducted. The objectives of this study were to deter-
mine the prevalence of oropharyngeal candidiasis and to define the
oral carrier status, Candida titers and species in this population.
Methods: 144 kidney and heart transplant subjects were recruited
from Hartford Hospital of whom 90 met the following criteria
and were included in analyses: 1. clinically stable; 2. at least
one year post transplant; 3. no history of antifungal or antibi-
otic use within the last 4 months. Control subjects (n=72) were
age- and sex-matched, systemically healthy individuals. Subjects
received an oral clinical examination. Swabs from the oral mucosa
and a standardized amount of unstimulated saliva were plated on
Chromagar® plates, and CFU/ml were calculated. Initial speciation
was based on colony color and was confirmed by standard germi-
nation and biotyping (carbohydrate assimilation) assays.
Results: Significantly more transplant (7.7%) than control (0%)
subjects had oral infection with C. albicans (p=0.004). A signif-
icantly higher (p=0.039) frequency of asymptomatic colonization
was noted in transplant recipients (51.1%) compared to healthy
controls (29.2%). In addition, the transplant group had signifi-
cantly higher Candida titers than the control group (p=0.04). There
was a significant positive association between diabetes and his-
tory of anti-fungals (p=0.039) and a significant negative associa-
tion between Cyclosporine treatment and history of anti-fungals
(p=0.0003). There were no statistically significant relationships be-
tween the dose or type of immunosuppressants and oral Candida
titers or infection. 13.3% of transplant carriers and 4.2% of the
control subjects were colonized by more than one species, a differ-
ence that was statistically significant (p=0.045). The most frequent
combination in transplant patients was C. albicans and C. glabrata.
C.glabrata was isolated in 7.8% of transplant patients and none
of the controls, a difference that was also statistically significant
(p=0.016).
Conclusions: Increased oral Candida infection and carriage titers
were found in solid organ transplant subjects who are at least one
year post-transplant. Although the majority of these subjects are
colonized by C. albicans, C.glabrata appears to emerge as the sec-
ond most prevalent species.
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De Novo T-Lymphocyte Responses against
Baculovirus-derived Recombinant Influenzavirus
Hemagglutinin Generated by a Naive Umbilical Cord Blood
Model of Dendritic Cell Vaccination
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Background: Cordblood-derived (CB) is an important source of
mostly unprimed stem cells. We sought to generate CB-derived
dendritic cells (DC) immunotherapy against influenzavirus.
Methods: Recombinant hemagglutinin (rHA) of H1N1 was expressed
by vector pPSC12 cloned baculovirus in SF9 cells. Generation of Im-
mature DCs. Umbilical cord blood units discarded from the MDACC
CB bank was used after IRB approval. DC loading and maturation:
in the presence of GM-CSF and IL-4, immature dendritic cells were
loaded with rHA protein. Immature DCs were suspended at a con-
centration of 4x107 cells/ml, mixed with rHA and incubated for
10 minutes on ice in an electroporation cuvette. T-cell priming
and re-Stimulation: matured loaded DCs were incubated at a ratio
of 1:10 with autologous non-adherent PBMCs (typically 50% CD3+),
plus IL-12. ELISpot Assay was performed using standard method.
ELISpots for putative HA peptide epitopes were performed similarly
using 1x 105 - 2x 105 lymphocytes incubated overnight in 3.75 mi-
crograms/ml peptide. T-cell specificity and functionality was then
demonstrated by 51Cr CTL lysis.
Results: rHA-specific lymphocytes demonstrate identifiable HLA-
restriction. HA-primed lymphocytes (HLA DRbeta1*1503) from a
different CB demonstrated a nine-fold increase in statistically large
spots when restimulated with the DR15-262 epitope (p<0.00002).
These data suggest that 1 in 1,900 of the HA-specific T-cells were
DR15-262 restricted in a highly-specific fashion. Total ELISpot num-
bers (p<0.0002) and total IFN-gamma release (p<0.00004) be-
tween lymphocytes restimulated with DR15-262 and the control
peptide were statistically distinct as well. Incubation of peptide
DR15-262 in conjunction with HA-primed/DR15- lymphocytes or
in conjunction with adenoviral hexon-primed (irrelevant) lympho-
cytes did not demonstrate significant numbers of IFN-gamma spots.
51Cr CTL assay demonstrates the generation of HA-specific cyto-
toxic T-cell effectors. Naïve cord blood T-cells were stimulated
three times with rHA-loaded dendritic cells; specific lysis of rHA-
loaded autologous DC was double that of unloaded control targets
at an E:T ratio of 5:1 (p=0.05).
